Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Search by expertise, name or affiliation
Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy: ValVET primary results
Joseph L. Izzo
, Howard S. Weintraub
,
Daniel A. Duprez
, Das Purkayastha
, Dion Zappe
, Rita Samuel
, William C. Cushman
Medicine - Cardiology Division
Lillehei Heart Institute
Research output
:
Contribution to journal
›
Article
›
peer-review
12
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy: ValVET primary results'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Monotherapy
100%
Hydrochlorothiazide
100%
Valsartan
100%
Super-elderly
100%
Systolic Hypertension
100%
Blood Pressure
10%
Angiotensin Receptor Blockers
10%
Initiating Treatment
10%
Median Time
10%
Antihypertensive Drugs
10%
Efficacy Outcomes
10%
Thiazides
10%
Blood Pressure Control
10%
25Mg
10%
Systolic Blood Pressure Reduction
10%
Single pill
10%
Pharmacology, Toxicology and Pharmaceutical Science
Systolic Hypertension
100%
Hydrochlorothiazide Plus Valsartan
100%
Monotherapy
100%
Hydrochlorothiazide
42%
Valsartan
42%
Antihypertensive Agent
14%
Angiotensin Receptor Antagonist
14%
Thiazide Diuretic Agent
14%